Valuation : Cogent Biosciences, Inc.

Market Cap 6.07B 5.22B 4.9B 4.48B 8.36B 573B 8.43B 57.94B 22.56B 293B 22.78B 22.28B 944B P/E 2026 *
-15.5x
P/E 2027 * -33.4x
Enterprise Value 5.94B 5.11B 4.79B 4.39B 8.19B 561B 8.25B 56.7B 22.08B 287B 22.29B 21.81B 924B EV / Sales 2026 *
991x
EV / Sales 2027 * 20.3x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -
1 day+1.10%
1 week-5.77%
Current month-0.14%
1 month-10.06%
3 months+8.34%
6 months-6.15%
Current year-1.60%
1 week 34.01
Extreme 34.01
35.82
1 month 34.01
Extreme 34.01
43.3
Current year 30.87
Extreme 30.87
43.39
1 year 11.6
Extreme 11.6
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap. Importance
27/08/26 Exercice

Director

136,530 0.0799%
01/07/26 Free

Director

627 0.0004%
09/06/26 Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
+1.10%-5.77%+167.20%+169.26% 6.07B
+0.41%-2.07%+41.26%+95.40% 69.02B
-1.51%+0.38%+42.32%+89.22% 66.32B
+0.04%+4.36%-11.72%+459.54% 27.66B
-0.90%-7.65%+2.45%-15.50% 25.84B
-3.00%-2.90%+39.40%+9.41% 26.54B
-0.27%+1.76%+25.73%-17.61% 20.4B
+3.45%-13.46%+222.69%+389.50% 17.63B
-1.49%-4.88%-0.41%+530.26% 15.15B
+1.03%+7.00%+59.98%+160.03% 14.65B
Average -0.11%-1.81%+58.89%+186.95% 28.93B
Weighted average by Cap. -0.41%-0.94%+44.17%+148.56%

Financials

2026 *2027 *
Net sales 5.99M 5.15M 4.84M 4.42M 8.26M 566M 8.32M 57.2M 22.28M 289M 22.49M 22M 932M 293M 252M 236M 216M 404M 27.67B 407M 2.8B 1.09B 14.14B 1.1B 1.08B 45.55B
Net income -399M -343M -322M -295M -550M -37.71B -554M -3.81B -1.48B -19.27B -1.5B -1.47B -62.07B -202M -173M -163M -149M -278M -19.05B -280M -1.92B -750M -9.74B -757M -740M -31.35B
Net Debt -130M -112M -105M -95.77M -179M -12.26B -180M -1.24B -482M -6.26B -487M -476M -20.17B -126M -108M -102M -93.15M -174M -11.92B -175M -1.2B -469M -6.09B -474M -463M -19.62B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
03/09/26 $34.95 +1.10% 1,268,646
02/09/26 $34.57 -0.32% 1,181,784
01/09/26 $34.68 -0.91% 1,480,641
31/08/26 $35.00 +0.95% 1,849,678
28/08/26 $34.67 -6.52% 1,771,221
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
34.95USD
Average target price
55.82USD
Spread / Average Target
+59.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock